Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patients

Bevacizumab plus chemotherapy was approved by the US Food and Drug Administration (FDA) as a first-line treatment for advanced nonsquamous, non-small-cell lung cancer (NSCLC) in 2006. This study retrospectively compared the efficacy of bevacizumab plus chemotherapy with chemotherapy alone as the fir...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Ning, Wang, Zhehai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973774/
https://www.ncbi.nlm.nih.gov/pubmed/27536131
http://dx.doi.org/10.2147/OTT.S110339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973774/
https://www.ncbi.nlm.nih.gov/pubmed/27536131
http://dx.doi.org/10.2147/OTT.S110339

Ejemplares similares